Sanofi (NASDAQ:SNY) is one of the globe's largest drug companies. It's a major player in diabetes treatments, vaccines, and consumer medicines, and is often included in dividend portfolios.

However, looming patent expiration on its top-selling drug, falling margin, and potential competition from Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) could all impact Sanofi's bottom line, and threaten Sanofi's dividend.

In the following slideshow, you'll learn whether I think Sanofi's dividend is safe, and see how Sanofi's dividend matches up to Lilly and Novo Nordisk.